KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Hypoxia inducible factor prolyl hydroxylase inhibitors: what a meta-analysis could tell us.

Francesco Locatelli, Carmine Zoccali

Clin Kidney J 17(1) sfad229

PMID38186887
PMCIDPMC10768760
DOI10.1093/ckj/sfad229
发表日期2024-01-08
摘要

摘要

Meta-analyses offer an estimate of the overall effect size and help address the inconsistency in findings across studies. The risk is the overemphasis on statistical significance while underrepresenting or misinterpreting clinical significance. There's also a lack of standardized methods for quantifying and reporting clinical significance and these measures are often missing or inconsistently reported in many meta-analyses, making it difficult for readers to determine the clinical relevance of the findings. A major merit of Minutolo's meta-analysis is to formally evaluate efficacy and safety of Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI) as class and as single agents in comparison with ESA, by selecting from only phase-3 randomised clinical trials (RCTs) that compared HIF-PHIs with erythropoiesis-stimulating agents (ESAs) in dialysis and non-dialysis patients. From a clinical perspective, the primary evaluation in this meta-analysis should have been the percentage of patients able to reach and maintain the target haemoglobin (Hb) levels throughout the trials but only a few RCTs selected this primary end point. Any claimed superiority of one drug over another should consider the selected doses. The amount of iron administered to patients, their iron stores and level of inflammation are important confounding factors that affect the reliability of any comparison.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。